S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
pixel
Log in
NASDAQ:ARCT

Arcturus Therapeutics Competitors

$53.96
-0.68 (-1.24 %)
(As of 03/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$53.34
Now: $53.96
$57.24
50-Day Range
$51.43
MA: $68.55
$86.92
52-Week Range
$8.51
Now: $53.96
$129.71
Volume668,077 shs
Average Volume1.61 million shs
Market Capitalization$1.32 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.01

Competitors

Arcturus Therapeutics (NASDAQ:ARCT) Vs. BHVN, SAGE, EIDX, ARNA, CCXI, and RETA

Should you be buying ARCT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Arcturus Therapeutics, including Biohaven Pharmaceutical (BHVN), Sage Therapeutics (SAGE), Eidos Therapeutics (EIDX), Arena Pharmaceuticals (ARNA), ChemoCentryx (CCXI), and Reata Pharmaceuticals (RETA).

Biohaven Pharmaceutical (NYSE:BHVN) and Arcturus Therapeutics (NASDAQ:ARCT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Insider and Institutional Ownership

99.4% of Biohaven Pharmaceutical shares are owned by institutional investors. Comparatively, 74.3% of Arcturus Therapeutics shares are owned by institutional investors. 19.1% of Biohaven Pharmaceutical shares are owned by insiders. Comparatively, 12.6% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Biohaven Pharmaceutical and Arcturus Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biohaven PharmaceuticalN/AN/A$-528,800,000.00($10.91)-7.58
Arcturus Therapeutics$20.79 million63.57$-25,990,000.00($2.15)-25.10

Arcturus Therapeutics has higher revenue and earnings than Biohaven Pharmaceutical. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Biohaven Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations for Biohaven Pharmaceutical and Arcturus Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biohaven Pharmaceutical02902.82
Arcturus Therapeutics25402.18

Biohaven Pharmaceutical currently has a consensus price target of $95.30, indicating a potential upside of 15.28%. Arcturus Therapeutics has a consensus price target of $70.6154, indicating a potential upside of 30.87%. Given Arcturus Therapeutics' higher possible upside, analysts clearly believe Arcturus Therapeutics is more favorable than Biohaven Pharmaceutical.

Profitability

This table compares Biohaven Pharmaceutical and Arcturus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biohaven PharmaceuticalN/A-1,091.41%-120.85%
Arcturus Therapeutics-506.70%-52.32%-33.21%

Risk and Volatility

Biohaven Pharmaceutical has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 3.01, suggesting that its stock price is 201% more volatile than the S&P 500.

Summary

Arcturus Therapeutics beats Biohaven Pharmaceutical on 7 of the 13 factors compared between the two stocks.

Arcturus Therapeutics (NASDAQ:ARCT) and Sage Therapeutics (NASDAQ:SAGE) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Earnings and Valuation

This table compares Arcturus Therapeutics and Sage Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcturus Therapeutics$20.79 million63.57$-25,990,000.00($2.15)-25.10
Sage Therapeutics$6.87 million715.03$-680,240,000.00($13.38)-6.29

Arcturus Therapeutics has higher revenue and earnings than Sage Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Sage Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Arcturus Therapeutics and Sage Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arcturus Therapeutics25402.18
Sage Therapeutics010702.41

Arcturus Therapeutics currently has a consensus price target of $70.6154, suggesting a potential upside of 30.87%. Sage Therapeutics has a consensus price target of $80.50, suggesting a potential downside of 4.33%. Given Arcturus Therapeutics' higher probable upside, equities analysts plainly believe Arcturus Therapeutics is more favorable than Sage Therapeutics.

Profitability

This table compares Arcturus Therapeutics and Sage Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arcturus Therapeutics-506.70%-52.32%-33.21%
Sage Therapeutics-7,706.84%-63.81%-56.64%

Institutional and Insider Ownership

74.3% of Arcturus Therapeutics shares are held by institutional investors. 12.6% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 4.8% of Sage Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Arcturus Therapeutics has a beta of 3.01, meaning that its share price is 201% more volatile than the S&P 500. Comparatively, Sage Therapeutics has a beta of 2.23, meaning that its share price is 123% more volatile than the S&P 500.

Summary

Arcturus Therapeutics beats Sage Therapeutics on 10 of the 14 factors compared between the two stocks.

Arcturus Therapeutics (NASDAQ:ARCT) and Eidos Therapeutics (NASDAQ:EIDX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Insider and Institutional Ownership

74.3% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 31.4% of Eidos Therapeutics shares are held by institutional investors. 12.6% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 70.1% of Eidos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Arcturus Therapeutics and Eidos Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcturus Therapeutics$20.79 million63.57$-25,990,000.00($2.15)-25.10
Eidos Therapeutics$26.69 million177.99$-37,830,000.00($1.03)-118.65

Arcturus Therapeutics has higher earnings, but lower revenue than Eidos Therapeutics. Eidos Therapeutics is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Arcturus Therapeutics and Eidos Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arcturus Therapeutics25402.18
Eidos Therapeutics18102.00

Arcturus Therapeutics currently has a consensus price target of $70.6154, suggesting a potential upside of 30.87%. Eidos Therapeutics has a consensus price target of $53.4520, suggesting a potential downside of 56.26%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Arcturus Therapeutics is more favorable than Eidos Therapeutics.

Profitability

This table compares Arcturus Therapeutics and Eidos Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arcturus Therapeutics-506.70%-52.32%-33.21%
Eidos TherapeuticsN/A-65.21%-53.04%

Volatility and Risk

Arcturus Therapeutics has a beta of 3.01, indicating that its stock price is 201% more volatile than the S&P 500. Comparatively, Eidos Therapeutics has a beta of -0.16, indicating that its stock price is 116% less volatile than the S&P 500.

Summary

Arcturus Therapeutics beats Eidos Therapeutics on 9 of the 14 factors compared between the two stocks.

Arcturus Therapeutics (NASDAQ:ARCT) and Arena Pharmaceuticals (NASDAQ:ARNA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, earnings, analyst recommendations and dividends.

Insider & Institutional Ownership

74.3% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of Arena Pharmaceuticals shares are owned by institutional investors. 12.6% of Arcturus Therapeutics shares are owned by company insiders. Comparatively, 3.1% of Arena Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Arcturus Therapeutics and Arena Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arcturus Therapeutics25402.18
Arena Pharmaceuticals001503.00

Arcturus Therapeutics presently has a consensus price target of $70.6154, suggesting a potential upside of 30.87%. Arena Pharmaceuticals has a consensus price target of $90.2143, suggesting a potential upside of 17.45%. Given Arcturus Therapeutics' higher probable upside, research analysts plainly believe Arcturus Therapeutics is more favorable than Arena Pharmaceuticals.

Profitability

This table compares Arcturus Therapeutics and Arena Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arcturus Therapeutics-506.70%-52.32%-33.21%
Arena PharmaceuticalsN/A-33.17%-30.41%

Risk & Volatility

Arcturus Therapeutics has a beta of 3.01, indicating that its share price is 201% more volatile than the S&P 500. Comparatively, Arena Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

Earnings & Valuation

This table compares Arcturus Therapeutics and Arena Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcturus Therapeutics$20.79 million63.57$-25,990,000.00($2.15)-25.10
Arena Pharmaceuticals$806.43 million5.75$397.55 million$7.699.99

Arena Pharmaceuticals has higher revenue and earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Arena Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Arena Pharmaceuticals beats Arcturus Therapeutics on 10 of the 14 factors compared between the two stocks.

ChemoCentryx (NASDAQ:CCXI) and Arcturus Therapeutics (NASDAQ:ARCT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations for ChemoCentryx and Arcturus Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ChemoCentryx01713.00
Arcturus Therapeutics25402.18

ChemoCentryx presently has a consensus target price of $80.7778, suggesting a potential upside of 20.92%. Arcturus Therapeutics has a consensus target price of $70.6154, suggesting a potential upside of 30.87%. Given Arcturus Therapeutics' higher probable upside, analysts plainly believe Arcturus Therapeutics is more favorable than ChemoCentryx.

Earnings and Valuation

This table compares ChemoCentryx and Arcturus Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ChemoCentryx$36.13 million127.96$-55,490,000.00($0.98)-68.16
Arcturus Therapeutics$20.79 million63.57$-25,990,000.00($2.15)-25.10

Arcturus Therapeutics has lower revenue, but higher earnings than ChemoCentryx. ChemoCentryx is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ChemoCentryx and Arcturus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ChemoCentryx-58.10%-17.23%-11.07%
Arcturus Therapeutics-506.70%-52.32%-33.21%

Volatility and Risk

ChemoCentryx has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 3.01, meaning that its share price is 201% more volatile than the S&P 500.

Insider & Institutional Ownership

80.7% of ChemoCentryx shares are owned by institutional investors. Comparatively, 74.3% of Arcturus Therapeutics shares are owned by institutional investors. 9.3% of ChemoCentryx shares are owned by insiders. Comparatively, 12.6% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

ChemoCentryx beats Arcturus Therapeutics on 10 of the 15 factors compared between the two stocks.

Reata Pharmaceuticals (NASDAQ:RETA) and Arcturus Therapeutics (NASDAQ:ARCT) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Volatility & Risk

Reata Pharmaceuticals has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 3.01, meaning that its stock price is 201% more volatile than the S&P 500.

Valuation & Earnings

This table compares Reata Pharmaceuticals and Arcturus Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Reata Pharmaceuticals$26.52 million166.37$-290,170,000.00($9.54)-13.56
Arcturus Therapeutics$20.79 million63.57$-25,990,000.00($2.15)-25.10

Arcturus Therapeutics has lower revenue, but higher earnings than Reata Pharmaceuticals. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Reata Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

64.3% of Reata Pharmaceuticals shares are owned by institutional investors. Comparatively, 74.3% of Arcturus Therapeutics shares are owned by institutional investors. 31.7% of Reata Pharmaceuticals shares are owned by company insiders. Comparatively, 12.6% of Arcturus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for Reata Pharmaceuticals and Arcturus Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Reata Pharmaceuticals00603.00
Arcturus Therapeutics25402.18

Reata Pharmaceuticals currently has a consensus price target of $251.25, indicating a potential upside of 94.27%. Arcturus Therapeutics has a consensus price target of $70.6154, indicating a potential upside of 30.87%. Given Reata Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Reata Pharmaceuticals is more favorable than Arcturus Therapeutics.

Profitability

This table compares Reata Pharmaceuticals and Arcturus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Reata Pharmaceuticals-4,340.72%-163.42%-56.49%
Arcturus Therapeutics-506.70%-52.32%-33.21%


Arcturus Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
1.6$82.67-4.5%$4.96 billionN/A-6.74Earnings Announcement
Analyst Report
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.2$84.14-3.7%$4.91 billion$6.87 million-8.13Earnings Announcement
Analyst Report
Analyst Revision
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.0$122.21-0.0%$4.75 billion$26.69 million-46.12
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.3$76.81-4.3%$4.63 billion$806.43 million-10.88
ChemoCentryx logo
CCXI
ChemoCentryx
1.4$66.80-2.4%$4.62 billion$36.13 million-99.70Earnings Announcement
Analyst Report
Insider Selling
Decrease in Short Interest
News Coverage
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$129.33-2.1%$4.41 billion$26.52 million-11.39Earnings Announcement
Hutchison China MediTech logo
HCM
Hutchison China MediTech
1.4$29.96-0.3%$4.36 billion$204.89 million-37.45Upcoming Earnings
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.1$23.74-0.5%$4.26 billion$114.62 million-9.57Earnings Announcement
Analyst Report
Analyst Revision
IMAB
I-Mab
0.9$58.90-8.6%$4.24 billion$4.31 million-2.04
Insmed logo
INSM
Insmed
1.2$38.45-1.9%$3.96 billion$136.47 million-14.79Earnings Announcement
Analyst Report
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$57.32-1.5%$3.91 billion$306.98 million-8.20Earnings Announcement
Analyst Revision
Arvinas logo
ARVN
Arvinas
1.9$77.51-0.3%$3.75 billion$42.98 million-30.28Earnings Announcement
Analyst Downgrade
Insider Selling
News Coverage
LEGN
Legend Biotech
1.2$26.28-0.6%$3.47 billion$64.39 million0.00Increase in Short Interest
FibroGen logo
FGEN
FibroGen
1.6$38.07-32.7%$3.46 billion$256.58 million-14.59Earnings Announcement
Analyst Downgrade
High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$45.60-4.6%$3.45 billionN/A-6.15Earnings Announcement
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.6$48.92-2.9%$3.39 billion$117.91 million-9.92Earnings Announcement
Analyst Downgrade
Analyst Revision
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.6$124.51-0.2%$3.36 billionN/A-61.95Earnings Announcement
Analyst Report
Analyst Revision
Gap Up
MorphoSys logo
MOR
MorphoSys
0.4$25.43-0.3%$3.35 billion$80.43 million121.10News Coverage
Gap Down
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.9$71.36-1.7%$3.10 billion$421.03 million25.13Earnings Announcement
Analyst Report
OPKO Health logo
OPK
OPKO Health
1.9$4.62-1.7%$3.10 billion$901.90 million-25.67
ALX Oncology logo
ALXO
ALX Oncology
1.9$83.34-5.2%$3.09 billionN/A0.00Upcoming Earnings
Decrease in Short Interest
Alkermes logo
ALKS
Alkermes
1.2$19.19-0.1%$3.06 billion$1.17 billion-41.72
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.6$54.94-1.5%$3.03 billionN/A-30.19Earnings Announcement
Analyst Report
Analyst Revision
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$11.17-5.6%$2.91 billion$182.24 million-9.71Earnings Announcement
Analyst Report
News Coverage
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.6$24.78-2.7%$2.91 billion$306.49 million27.84
Viela Bio logo
VIE
Viela Bio
0.8$52.93-0.0%$2.91 billion$50 million-7.54Earnings Announcement
Decrease in Short Interest
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$34.44-1.5%$2.79 billion$60,000.00-10.70Earnings Announcement
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.01-1.2%$2.75 billion$644.77 million-10.27High Trading Volume
Increase in Short Interest
IGMS
IGM Biosciences
1.5$89.27-3.6%$2.74 billionN/A-37.99
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.6$44.03-1.0%$2.74 billion$2.11 million-9.53Analyst Revision
PRLD
Prelude Therapeutics
1.0$62.53-8.3%$2.73 billionN/A0.00
Xencor logo
XNCR
Xencor
1.0$46.05-5.0%$2.67 billion$156.70 million-32.89Analyst Upgrade
Analyst Revision
Axsome Therapeutics logo
AXSM
Axsome Therapeutics
1.6$69.76-0.8%$2.61 billionN/A-25.93Earnings Announcement
Analyst Report
News Coverage
Arcus Biosciences logo
RCUS
Arcus Biosciences
2.0$36.27-1.2%$2.57 billion$15 million-18.99Analyst Revision
Deciphera Pharmaceuticals logo
DCPH
Deciphera Pharmaceuticals
1.6$44.31-0.8%$2.55 billion$25 million-8.86
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$152.86-2.4%$2.54 billion$120.28 million-154.40Decrease in Short Interest
Amarin logo
AMRN
Amarin
1.6$6.03-2.7%$2.34 billion$429.76 million-120.58Earnings Announcement
Cryoport logo
CYRX
Cryoport
1.5$59.01-5.9%$2.34 billion$33.94 million-101.74Earnings Announcement
Analyst Upgrade
News Coverage
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.8$29.51-2.1%$2.21 billion$23.90 million-18.33Earnings Announcement
Analyst Report
High Trading Volume
News Coverage
Gap Down
MORF
Morphic
1.1$71.06-19.4%$2.21 billion$16.98 million-45.55Earnings Announcement
Analyst Report
Insider Selling
High Trading Volume
Decrease in Short Interest
News Coverage
Gap Up
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$24.24-1.6%$2.20 billionN/A-8.63
Generation Bio logo
GBIO
Generation Bio
1.4$38.29-5.0%$2.13 billionN/A0.00Analyst Report
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.6$42.01-0.6%$2.09 billion$963.01 million13.05
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
1.3$59.81-5.4%$2.09 billionN/A0.00Upcoming Earnings
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.0$60.00-1.9%$2.01 billionN/A-33.33High Trading Volume
HRMY
Harmony Biosciences
1.2$34.90-3.8%$1.99 billionN/A0.00Upcoming Earnings
Analyst Downgrade
Kura Oncology logo
KURA
Kura Oncology
1.6$29.98-0.1%$1.99 billionN/A-18.39Earnings Announcement
Analyst Report
Analyst Revision
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.7$27.26-0.4%$1.88 billion$103.54 million-20.50Insider Selling
ADCT
ADC Therapeutics
1.6$27.08-0.9%$1.87 billion$2.34 million-11.47Upcoming Earnings
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
2.0$14.42-0.4%$1.84 billion$320,000.00-9.81Analyst Revision
This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.